Clinical Trials
6 trialsNCT02487979 2022-01-18
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02363283 2020-08-21
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02713828 2019-07-16
PrE0504
PrECOG, LLC.
Phase 1/2 Terminated
NCT03326258 2018-07-18
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT00412828 2015-02-19
A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma
Celldex Therapeutics
Phase 1/2 Completed
NCT00704158 2015-02-19
Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer
Celldex Therapeutics
Phase 1/2 Completed